Drug Profile
Streptococcal B vaccine recombinant - ID Biomedical
Latest Information Update: 04 Feb 2008
Price :
$50
*
At a glance
- Originator ID Biomedical Corporation
- Class Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Streptococcal infections
Most Recent Events
- 04 Feb 2008 Discontinued - Preclinical for Streptococcal infections in USA (Parenteral)
- 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
- 21 Sep 2004 Shire Biologics has been acquired and merged into ID Biomedical Corporation